Clinical Study to Measure Pharmacokinetics, Pharmacodynamics and Safety of a TDF

测量 TDF 的药代动力学、药效学和安全性的临床研究

基本信息

  • 批准号:
    8210597
  • 负责人:
  • 金额:
    $ 46.11万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-10 至
  • 项目状态:
    未结题

项目摘要

The ultimate goal of this Program is to develop an intravaginal ring (IVR) for sustained delivery of a combination microbicide that will be safe and effective in preventing the sexual transmission of human immunodeficiency virus (HIV) and herpes simplex virus (HSV). A safe and effective microbicide will likely require sustained, local delivery of a combination of antiretroviral drugs that target different steps in the HIV life cycle and a delivery system that overcomes the challenges related to adherence. This will be accomplished through IVR formulation of the reverse transcriptase inhibitor, tenofovir disoproxil fumarate (TDF), combined with the entry inhibitor, maraviroc (MVC). The rationale for pursuing this combination is based on the recent promising results of CAPRISA 004 in which significant protection against HIV-1 and HSV-2 was observed with 1% TFV gel. Ongoing work in Projects 1 and 2 demonstrate potential advantages of a TDF compared to a TFV IVR, including more potent activity against HIV and HSV, greater tissue permeability, and the successful development of a polyurethane (PU) IVR formulation of TDF. An exploratory pre-Phase I study is proposed in this new Project to rigorously measure the pharmacokinetics (PK), pharmacodynamics (PD) and safety of TDF following ring delivery in healthy women. The primary outcomes to be measured are PK of TDF release into the genital tract and adverse events. PD will be evaluated by measuring the antiviral activity (HIV and HSV) in genital tract secretions (luminal) and tissue following IVR delivery of TDF. Ectocervical tissue will be challenged ex vivo with virus to assess drug bioavailability and activity. The impact of PU IVRs on the mucosal immune environment will be assessed by quantifying immune cell populations in the genital tract and concentrations of inflammatory, anti-inflammatory and soluble mucosal immune mediators in genital tract secretions. Advanced molecular microbiological tools will be employed including broad range 16S rRNA gene PCR with pyrosequencing to define the bacterial communities, and fluorescence in situ hybridization to determine if rings alter the epithelium and lead to vaginal biofilm formation. Results will inform the design of a Phase I trial of a TDF-MVC combination IVR.
该项目的最终目标是开发一种阴道内环(IVR),用于持续递送一种联合杀微生物剂,该杀微生物剂将安全有效地预防人类免疫缺陷病毒(HIV)和单纯疱疹病毒(HSV)的性传播。一种安全有效的杀微生物剂可能需要针对艾滋病毒生命周期不同阶段的抗逆转录病毒药物组合的持续局部递送,以及克服与依从性相关的挑战的递送系统。这将通过逆转录酶抑制剂富马酸替诺福韦二氧吡酯(TDF)与进入抑制剂马拉维洛克(MVC)的IVR配方来实现。寻求这种组合的基本原理是基于CAPRISA 004最近的有希望的结果,其中1%的TFV凝胶观察到对HIV-1和HSV-2的显着保护。项目1和项目2中正在进行的工作表明,与TFV IVR相比,TDF具有潜在的优势,包括更有效的抗HIV和HSV活性,更强的组织渗透性,以及TDF聚氨酯(PU) IVR配方的成功开发。本项目拟开展一项探索性I期前期研究,严格测量健康女性环分娩后TDF的药代动力学(PK)、药效学(PD)和安全性。要测量的主要结果是TDF释放到生殖道的PK和不良事件。PD将通过测量生殖道分泌物(管腔)和组织中的抗病毒活性(HIV和HSV)来评估

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARLA J KELLER其他文献

MARLA J KELLER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARLA J KELLER', 18)}}的其他基金

Einstein-Montefiore Clinical and Translational Science Award Hub
爱因斯坦-蒙蒂菲奥里临床和转化科学奖中心
  • 批准号:
    10622099
  • 财政年份:
    2023
  • 资助金额:
    $ 46.11万
  • 项目类别:
Convalescent Plasma to Limit Coronavirus Associated Complications: A Randomized Blinded Phase 2 Study Comparing the Efficacy and Safety of Anti-SARS-CoV-2 Plasma to Placebo in COVID-19 hospitalized pa
恢复期血浆限制冠状病毒相关并发症:一项随机盲法 2 期研究,比较抗 SARS-CoV-2 血浆与安慰剂在 COVID-19 住院患者中的功效和安全性
  • 批准号:
    10166008
  • 财政年份:
    2020
  • 资助金额:
    $ 46.11万
  • 项目类别:
CTSA Administrative Supplement for Informatics Core: A novel AI/ML system to predict respiratory failure and ARDS in Covid-19 patients
CTSA 信息学核心行政补充:一种预测 Covid-19 患者呼吸衰竭和 ARDS 的新型 AI/ML 系统
  • 批准号:
    10158737
  • 财政年份:
    2020
  • 资助金额:
    $ 46.11万
  • 项目类别:
Clinical and Translational Science Award
临床和转化科学奖
  • 批准号:
    10112978
  • 财政年份:
    2018
  • 资助金额:
    $ 46.11万
  • 项目类别:
Clinical and Translational Science Award
临床和转化科学奖
  • 批准号:
    9886296
  • 财政年份:
    2018
  • 资助金额:
    $ 46.11万
  • 项目类别:
Clinical and Translational Science Award
临床和转化科学奖
  • 批准号:
    10357784
  • 财政年份:
    2018
  • 资助金额:
    $ 46.11万
  • 项目类别:
Modifies of PrEP Efficacy in US & African Women: Age, Hormones, Sex & Microbiota
美国 PrEP 疗效的修改
  • 批准号:
    8448509
  • 财政年份:
    2013
  • 资助金额:
    $ 46.11万
  • 项目类别:
Safety of Non-Medicated Intravaginal Rings for Microbicide Delivery
用于杀菌剂递送的非药物阴道环的安全性
  • 批准号:
    8012508
  • 财政年份:
    2010
  • 资助金额:
    $ 46.11万
  • 项目类别:
EFFECTS OF HORMONES ON MUCOSAL IMMUNE MEDIATORS ACROSS THE MENSTRUAL CYCLE
激素对整个月经周期粘膜免疫介质的影响
  • 批准号:
    7718170
  • 财政年份:
    2008
  • 资助金额:
    $ 46.11万
  • 项目类别:
EFFECTS OF HORMONES ON MUCOSAL IMMUNE MEDIATORS ACROSS THE MENSTRUAL CYCLE
激素对整个月经周期粘膜免疫介质的影响
  • 批准号:
    7605356
  • 财政年份:
    2007
  • 资助金额:
    $ 46.11万
  • 项目类别:

相似海外基金

Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10707830
  • 财政年份:
    2023
  • 资助金额:
    $ 46.11万
  • 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
  • 批准号:
    479728
  • 财政年份:
    2023
  • 资助金额:
    $ 46.11万
  • 项目类别:
    Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
  • 批准号:
    10884567
  • 财政年份:
    2023
  • 资助金额:
    $ 46.11万
  • 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
  • 批准号:
    10751964
  • 财政年份:
    2023
  • 资助金额:
    $ 46.11万
  • 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
  • 批准号:
    486321
  • 财政年份:
    2022
  • 资助金额:
    $ 46.11万
  • 项目类别:
    Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10676786
  • 财政年份:
    2022
  • 资助金额:
    $ 46.11万
  • 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10440970
  • 财政年份:
    2022
  • 资助金额:
    $ 46.11万
  • 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
  • 批准号:
    10642998
  • 财政年份:
    2022
  • 资助金额:
    $ 46.11万
  • 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10482465
  • 财政年份:
    2022
  • 资助金额:
    $ 46.11万
  • 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
  • 批准号:
    10191053
  • 财政年份:
    2020
  • 资助金额:
    $ 46.11万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了